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008, the DPT dropout rate in Kabarole was high (18%). This
tudy assessed the service, community and individual factors
ssociated with DPT1-3 dropout in Kabarole District.
Methods: A cross sectional study using cluster sampling
as employed. Two clusters at parish level (rural and urban)
ach from a county in the district were selected by sim-
le random sampling and all villages therein were studied.
total of 230 children (115 from either cluster) were
ecruited and their parent or guardian interviewed. Cross-
abulations and chi-square tests were used to determine the
trength of associations between independent variables and
he outcome. Binary logistic regression was done to adjust
or potential confounders and identify independent predic-
ors. Key informant interviews were held with in-charges of
ealth units. Qualitative data was analysed manually using
hematic approach and results presented in the form of text.
Results: Factors found to be associated with DPT1-3
ropout were; lack of caretaker knowledge about DPT
osage, (adj. OR = 8.2; 95% CI: 3.12, 21.53); Child’s Birth
rder, 6th and above (adj. OR = 3.0; 95% CI: 0.80, 11.05);
hild Birth Order 2-3 (adj. OR = 2.2; 95% CI: 0.70, 6.71);
hild age group 31-36 compared to 12-18 (adj. OR = 2.5; 95%
I: 0.81, 7.84). However, Rural residence (OR = 1.2; 95% CI:
.56, 2.57); and Child without immunisation card (OR = 4.4;
5% CI: 0.35, 39.86) were not signiﬁcantly associated with
PT dropout.
Conclusion: The current DPT1-3 dropout prevalence in
abarole is still high but dropping (13.7%). DPT 1-3 dropout
s associated with caretaker lack of knowledge of number of
osages a child should receive and involvement of religious
eaders, long travel distance to point of accessing trans-
ort means, and convenient time for immunisation. Findings
rom this study can be used to improve DPT immunisation
ervices. Speciﬁc campaigns on DPT immunisation through
ome visits, involving community leaders and full day immu-
isation can help further reduce the dropout rate.
oi:10.1016/j.ijid.2010.02.626
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Background: In a clinical trial in ambulatory older adults,
st and 2nd PN23 doses induced signiﬁcant increases in IgG
ntibody and were generally well tolerated. We re-enrolled
rial participants to study 10-year antibody persistence fol-
owing the earlier doses, and immunogenicity and safety of
nd or 3rd PN23 doses.Methods: Ten years after receiving a 1st or 2nd PN23
ose, 143 trial participants (age 60-93 years, median 77)
ere re-enrolled and revaccinated (2nd dose n = 72, 3rd dose
= 71). Sera obtained before and 30 days postvaccination
r
l
t
aternational Congress on Infectious Diseases (ICID) Abstracts
ere analyzed by ELISA for IgG to vaccine serotypes 3, 4,
B, 8, 9 V, 12F, 14, and 23F. Participants recorded all adverse
xperiences (AEs) through 14 days postvaccination. Serious
Es were monitored through 30 days postvaccination.
Results: Ten years postvaccination, geometric mean con-
entrations (GMCs) in 1st- and 2nddose recipients remained
igher than prevaccination GMCs in 1st-dose subjects (when
hey were vaccine-naive) for all but serotype 3. Second
nd 3rd doses induced signiﬁcant increases in GMCs for
and 6 serotypes, respectively; GMCs for all 8 serotypes
ncreased in participants < and ‘‘75 years old. Frequencies
f injection-site and systemic AEs were lower after the 2nd
han the 3rd dose. Among 3rd-dose recipients, injection-site
ain, swelling, and redness were reported by 75%, 39%, and
0%, respectively, while fatigue, body aches, and headache
ere reported by 38%, 34%, and 25%, respectively. Fever
oral temperature ‘‘100 ◦F [37.8 ◦C]) occurred in 0% and 6%
f 2nd- and 3rd-dose recipients, respectively; the maxi-
um reported temperature was 100.2 ◦F (37.9 ◦C). AEs after
ither dose were generally mild, and > 90% resolved within
week. No vaccine-related serious AEs were reported.
Conclusion: Although protective levels have not been
stablished for adults, antipneumococcal antibody is known
o protect against pneumococcal disease. In ambulatory
lder adults, 1st and 2nd PN23 doses induced IgG antibody to
accine serotypes which still exceeded vaccine-naive levels
fter 10 years. Moreover, 2nd and 3rd doses administered 10
ears after the previous dose were immunogenic and gen-
rally well tolerated in those < and ‘‘75 years old. These
ndings are consistent with a beneﬁcial effect of 1st, 2nd,
nd 3rd PN23 doses.
oi:10.1016/j.ijid.2010.02.627
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Background: Argentine has been polio free since 1984 and
as a sustained and active surveillance of the acute ﬂaccid
aralysis (AFP) that involves an epidemiology and laboratory
pproach, reaching all the PAHO indicators. In this context
e describe the emergence of a case of AFP due to an VDPV
n a 15-months old boy with polyclonal agammaglobuline-
ia.
Methods: The case was notiﬁed to the National Program,
nd a stool sample and a throat swab were sent to the
egional Reference Center for Polio Diagnosis. Samples were
noculated in Rd and L20B cells following the new algorithm
ecommended by WHO. In less than 2 days a virus was iso-
ated in both samples which were characterized as a polio
ype 1. They were sequenced in the VP1 region, 5ˇıNCR. As
result we found a 3,7% (stool sample) and 3,5% (throat
